Side-by-side · Research reference

DermorphinvsHCG

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED20/47 cited

BFDA-ApprovedHUMAN-REVIEWED12/52 cited

Dermorphin

Opioid Peptide · μ-Receptor Agonist · Research Only

~30×Morphine potency

μ-selectiveReceptor typeNegri 1992

D-Ala²Unique featureAmiche 1998

Research only · ICV / SC (animal models)

HCG

Glycoprotein Hormone · LH Mimetic

2,000 IUTypical dose (2×/wk)Konsam 2026 Zachariou 2026

70–90%Sperm induction rateHuijben 2026 Zachariou 2026

12–24 moTime to sperm appearanceHuijben 2026 Nariyoshi 2025

IM or SQ · 2–3×/week

01Mechanism of Action

Parameter

Dermorphin

HCG

Primary target

μ-opioid receptors (central and peripheral)Negri 1992 Steel 2014

LH receptors on testicular Leydig cellsSchröder-Lange 2025

Pathway

μ-receptor activation → G-protein coupling → adenylyl cyclase inhibition → neuronal hyperpolarization

hCG → Leydig cell LH receptor → Intracellular cAMP → Steroidogenesis pathway activation → Testosterone synthesis

Downstream effect

Potent analgesia, reduced nociceptive signaling, opioid-mediated CNS and peripheral effects

Elevated intratesticular testosterone, restored spermatogenesis, virilization, secondary sex characteristic developmentKonsam 2026 Zachariou 2026

Feedback intact?

N/A — exogenous opioid agonist

No — exogenous hCG bypasses hypothalamic-pituitary axis; endogenous LH remains suppressed

Origin

Phyllomedusa sauvagei and P. bicolor frog skin — gene-encoded with natural D-amino acid incorporationAmiche 1998 Mignogna 1992

Heterodimeric glycoprotein (alpha subunit shared with LH/FSH/TSH; beta subunit confers specificity). Available as urinary-derived or recombinant formulations.

Antibody development

Site-directed antibodies produced for detection and purificationCucumel 1996

Rare with recombinant; possible with urinary-derived formulations

02Dosage Protocols

Parameter

Dermorphin

HCG

Legal status

Controlled substance in many jurisdictions · Research only

Not approved for human use.

—

Animal research (ICV)

Low nanomolar to picomolar range

Intracerebroventricular administration in rodent models.

—

Detection limit (doping)

5 pg/mL in equine plasma/urineSteel 2014

High-throughput LC-MS/MS screen developed for racing industry.

—

Duration of action

10–120 minutes (dose-dependent, intrathecal)

—

Evidence basis

Animal studies · In vitro assays

RCT / Meta-analysis / FDA-approvedKonsam 2026 Huijben 2026

Human toxicity

Kambô ritual (P. bicolor skin) — violent emesis, vasodilation, fluid shifts, ADH dysregulationTran 2025

—

Hypogonadotropic hypogonadism (monotherapy)

—

2,000 IU IM/SQ 2–3×/weekKonsam 2026 Zachariou 2026

Titrate to normalize testosterone (300–1,000 ng/dL) or achieve target AMH ~7.4 ng/mL.

Combined therapy (hCG + FSH)

—

hCG 2,000 IU 2×/wk + rFSH 75 IU 3×/wkKonsam 2026 Nariyoshi 2025

Preferred for azoospermia; FSH added after initial hCG phase or from outset.

Triple therapy (experimental)

—

hCG 2,000 IU 2×/wk + rFSH 75 IU 3×/wk + testosterone 100 mg IM q2wkKonsam 2026

May accelerate virilization; reduces hCG requirements (~30% lower cumulative dose vs monotherapy).

Cryptorchidism (pediatric)

—

500–4,000 IU IM 2–3×/week for 3–6 weeks

Duration to sperm appearance

—

12–24 months (median ~18 mo)Huijben 2026 Zachariou 2026

Congenital HH may require longer treatment; acquired HH responds faster.

Route

—

Intramuscular or subcutaneousKonsam 2026

Monitoring

—

Serum testosterone, semen analysis q3–6mo, testicular ultrasound

Thickened seminiferous tubules (>300 μm) on ultrasound predict imminent sperm appearance.Nariyoshi 2025

04Side Effects & Safety

Parameter

Dermorphin

HCG

Opioid effects

Respiratory depression, sedation, euphoria, tolerance, dependence risk

—

CNS effects

Analgesia (high-affinity sites), catalepsy (low-affinity sites)Negri 1992

—

Kambô ritual toxicity

Violent emesis, vasodilation, profound fluid shifts, hyponatremia, ADH dysregulation, brain death (case report)Tran 2025

—

Peripheral effects

GI motility inhibition (ileum > vas deferens in vitro)Negri 1992

—

Receptor selectivity caveat

Two μ-receptor subtypes — differential behavioral effects (analgesia vs. catalepsy)Negri 1992

—

Proteolytic stability

Tyr³-Pro⁶ bond relatively unstable; endogenous enzymes may produce tetrapeptide fragmentsCucumel 1996

—

Injection site reaction

—

Pain, erythema (mild, transient)

Gynecomastia

—

Aromatization of elevated testosterone to estradiol; dose-dependent

Testicular discomfort / Edema

—

Rapid testicular growth in hypogonadal males; usually self-limiting

Polycythemia

—

Elevated hematocrit from supraphysiological testosterone; monitor CBC

Mood / Libido changes

—

Variable; usually positive with normalization of testosterone

Acne / Oily skin

—

Androgen-mediated; dose-dependent

Prostate concerns

—

Monitor PSA in older males; hCG restores physiological testosterone (not supraphysiological)

Antibody formation

—

Rare with recombinant; possible with urinary-derived

Absolute Contraindications

Dermorphin

·Human use — not approved by any regulatory authority
·Controlled substance status — possession illegal in many jurisdictions
·Known opioid hypersensitivity or respiratory compromise

HCG

·Androgen-dependent malignancy (prostate, breast cancer)
·Hypersensitivity to hCG or excipients
·Precocious puberty

Relative Contraindications

Dermorphin

·Any context outside approved animal research protocols
·CNS depressant co-administration

HCG

·Untreated obstructive sleep apnea
·Severe cardiovascular disease (polycythemia risk)
·History of thromboembolism

05Administration Protocol

Parameter

Dermorphin

HCG

1. Legal and ethical framework

Dermorphin is a controlled substance in many jurisdictions and is not approved for human use. Possession, synthesis, or distribution may be illegal. Use is restricted to licensed research settings under institutional review.

Add sterile water or bacteriostatic water per manufacturer instructions. Typically 1–2 mL per 5,000–10,000 IU vial. Roll gently — do not shake. Solution should be clear.

2. Animal research protocols

In rodent models, intracerebroventricular (ICV) or intrathecal injection is used at nanomolar to picomolar concentrations. Subcutaneous administration also documented. All protocols require IACUC approval.

Intramuscular: ventrogluteal, vastus lateralis, or deltoid. Subcutaneous: abdomen, avoiding navel (2-inch radius). Rotate sites to prevent lipohypertrophy.

3. Analytical detection

High-throughput LC-MS/MS screens developed for anti-doping programs detect dermorphin and 17 related peptides in equine and human urine/plasma at limits as low as 5 pg/mL.Steel 2014

Administer 2–3 times per week. Consistent weekly schedule recommended (e.g., Monday/Thursday or Monday/Wednesday/Friday).

4. Kambô ritual (traditional use)

Application of Phyllomedusa bicolor skin secretions to superficial burns. Not recommended — associated with severe toxicity including violent emesis, hyponatremia, and documented case of brain death.Tran 2025

Lyophilized: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C. Bacteriostatic water extends shelf life to ~30 days; sterile water use within 72 hours.

5. Needle selection

—

IM: 21–23G, 1–1.5 inch. SQ: 25–27G, 5/8 inch. Inject slowly (30–60 seconds for IM).